 Zacks Investment Research upgraded shares of Eidos Therapeutics NASDAQ:EIDX from a hold rating to a buy rating in a report published on Monday morning, Zacks.com reports. They currently have 60.00 target price on the stock. According to Zacks, Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It discovers and develops novel oral therapy for ... 